
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics Inc. is poised for significant growth, with annual sales of Korlym projected to increase by 19% to 26% year-over-year for FY2025, reflecting strong underlying demand and the company's ability to overcome recent supply chain challenges. The encouraging clinical trial results for relacorilant, particularly in combination with nab-paclitaxel for advanced ovarian cancer, highlight the compound's potential to significantly improve patient outcomes, further enhancing the company's prospects. Additionally, the ongoing expansion of the Cushing’s syndrome market and anticipated improvements in production capacity indicate that Corcept could tap into a multi-billion-dollar market in the coming years.
Bears say
Corcept Therapeutics faces potential near-term earnings challenges, as the departure of Optime and anticipated downward revisions to 2025 revenue guidance may negatively impact investor sentiment. The company has lowered its Korlym sales forecast by approximately 10% for the latter half of 2025, which has resulted in a projected 2025 sales estimate of $824 million, falling below the previously expected range of $850 million to $900 million. Additionally, delays in management's strategy to establish operational pharmacies are exacerbating supply chain issues, contributing to increased uncertainty regarding future revenue growth.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares